Viridian Therapeutics won U.S. FDA clearance for Lumvoa (veligrotug-vvze) for thyroid eye disease, with labeling covering both chronic and active phases. The approval positions the IGF-1R antagonist to compete with Amgen’s Tepezza (teprotumumab-trbw), which has been the established targeted therapy since its 2020 approval. Analysts flagged that Lumvoa’s label includes safety language broadly aligned with Tepezza and emphasizes effects on diplopia response and complete diplopia resolution across active and chronic forms. Viridian also launched a patient-support program, Viridiancares, aimed at easing treatment access. The clearance is Viridian’s path to commercialization for its first product and raises payer and utilization questions in a crowded space where dosing logistics and response durability often drive formulary decisions.